Herantis Pharma Plc, Company release, 2 October 2024 at 13:15 EEST

Composition of Herantis Pharma Plc's Shareholders' Nomination Committee

The following members have been appointed to Herantis Pharma's Shareholders' Nomination Committee:

• Kyösti Kakkonen, representing Joensuun Kauppa ja Kone Oy (Chair),
• Pia Gisgård, representing Swedbank Robur,
• Timo Syrjälä, representing himself and Acme Investments SPF S.à.r.l., and
• Timo Veromaa, the Chair of Herantis Pharma's Board of Directors.

Herantis Pharma's Shareholders' Nomination Committee consists of four members, of which three represent the Company's shareholders. The Chair of Herantis Pharma's Board of Directors will serve as the fourth member of the Nomination Committee.

The Shareholders' Nomination Committee prepares and presents to the Annual General Meeting proposals on the remuneration, number and members of the Board of Directors.

For more information, please contact:

Tone Kvåle, CFO

Tel: +47 915 19576

Email: ir@herantis.com

Certified Advisor:

UB Corporate Finance Ltd

Tel: +358 9 25 380 225

E-mail: ubcf@unitedbankers.fi

About Herantis Pharma Plc

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson's disease. Herantis' lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. The primary aim of the ongoing Phase 1b clinical trial is to show that repeated subcutaneous doses of HER-096 are safe and well-tolerated in patients with Parkinson's disease. The Phase 1a clinical trial demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in healthy volunteers.

The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Company website: www.herantis.com